Loading…
Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin
WHT/Ht mice transplanted s.c. with NC carcinoma were treated with 16,16-dimethyl prostaglandin E2 methyl ester (di-me-PGE2) and/or indomethacin. Each primary tumour was excised under anaesthesia 3 weeks after transplantation, weighed and extracted for prostaglandins. Mouse survival time and tumour r...
Saved in:
Published in: | British journal of cancer 1985-08, Vol.52 (2), p.245-249 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3614-3f6134011b4953fe34dfae144bd001459ea125aab855bf8a31016d52065ff5bf3 |
---|---|
cites | |
container_end_page | 249 |
container_issue | 2 |
container_start_page | 245 |
container_title | British journal of cancer |
container_volume | 52 |
creator | Bennett, A Carroll, M A Melhuish, P B Stamford, I F |
description | WHT/Ht mice transplanted s.c. with NC carcinoma were treated with 16,16-dimethyl prostaglandin E2 methyl ester (di-me-PGE2) and/or indomethacin. Each primary tumour was excised under anaesthesia 3 weeks after transplantation, weighed and extracted for prostaglandins. Mouse survival time and tumour recurrence were measured. Di-me-PGE2 10 micrograms, injected at the tumour site on alternate days from day 1 to 19, indomethacin 2.5 mg kg-1 daily by mouth, or both drugs together resulted in lighter tumours (respectively 45, 45 and 52% less, n = 18 to 20 per group, P less than 0.02) compared with vehicle-treated controls. Indomethacin reduced the tumour prostaglandin yield, but the biological activity in extracts of tumours from mice given di-me-PGE2 was high. The median survival time was longer in mice receiving indomethacin alone (61 days from tumour transplantation compared with 50 days in controls P less than 0.02). Di-me-PGE2 alone had little or no effect on survival (median 48 days) but counteracted the increase with indomethacin (di-me-PGE2 + indomethacin, 49 days median survival). There were no obvious effects of the treatments on tumour recurrence at the excision site, but there was a higher incidence of involved lymph nodes in mice given di-me-PGE2. |
doi_str_mv | 10.1038/bjc.1985.184 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1977112</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76254612</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3614-3f6134011b4953fe34dfae144bd001459ea125aab855bf8a31016d52065ff5bf3</originalsourceid><addsrcrecordid>eNptkc1v1DAQxS1EVZbCjStSDogTWTz-inNBQlWBSpV6KVytiWPvepXEi50s4r_HZVcrkHryx_t5xvMeIW-AroFy_bHb2TW0Wq5Bi2dkBZKzGjRrnpMVpbSpacvoC_Iy5105tlQ3l-RSUNaAUivy4yE5nEc3zVX01RiX7CqLyYYpjliFqTqEQ6x-hXlbYbVPMc-4GXDqi3LDKpxwiJvFlU1f4D6Obt5iefyKXHgcsnt9Wq_I9y83D9ff6rv7r7fXn-9qyxWImnsFXFCATrSSe8dF79GBEF1PKQjZOgQmETstZec1cqCgesmokt6XG35FPh3r7pdudL0tcyQczD6FEdNvEzGY_5UpbM0mHgy0TQPASoH3pwIp_lxcns0YsnVDmdEVM0yjmBTqL_jhCNpiQk7On5sANY85mJKDeczBlBwK_vbfj53hk_FFf3fSMVscfMLJhnzGtGJcaV2w-ojlokwbl8wuLqm4np9u-wcGSqAT</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76254612</pqid></control><display><type>article</type><title>Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin</title><source>PubMed Central</source><creator>Bennett, A ; Carroll, M A ; Melhuish, P B ; Stamford, I F</creator><creatorcontrib>Bennett, A ; Carroll, M A ; Melhuish, P B ; Stamford, I F</creatorcontrib><description>WHT/Ht mice transplanted s.c. with NC carcinoma were treated with 16,16-dimethyl prostaglandin E2 methyl ester (di-me-PGE2) and/or indomethacin. Each primary tumour was excised under anaesthesia 3 weeks after transplantation, weighed and extracted for prostaglandins. Mouse survival time and tumour recurrence were measured. Di-me-PGE2 10 micrograms, injected at the tumour site on alternate days from day 1 to 19, indomethacin 2.5 mg kg-1 daily by mouth, or both drugs together resulted in lighter tumours (respectively 45, 45 and 52% less, n = 18 to 20 per group, P less than 0.02) compared with vehicle-treated controls. Indomethacin reduced the tumour prostaglandin yield, but the biological activity in extracts of tumours from mice given di-me-PGE2 was high. The median survival time was longer in mice receiving indomethacin alone (61 days from tumour transplantation compared with 50 days in controls P less than 0.02). Di-me-PGE2 alone had little or no effect on survival (median 48 days) but counteracted the increase with indomethacin (di-me-PGE2 + indomethacin, 49 days median survival). There were no obvious effects of the treatments on tumour recurrence at the excision site, but there was a higher incidence of involved lymph nodes in mice given di-me-PGE2.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1985.184</identifier><identifier>PMID: 4027166</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>16,16-Dimethylprostaglandin E2 - pharmacology ; Animals ; Antineoplastic agents ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoma - analysis ; Carcinoma - drug therapy ; Carcinoma - mortality ; Carcinoma - pathology ; Drug Resistance ; Epidemiology ; General aspects ; Indomethacin - antagonists & inhibitors ; Indomethacin - therapeutic use ; Male ; Medical sciences ; Mice ; Mice, Inbred Strains ; Molecular Medicine ; Neoplasm Transplantation ; Oncology ; original-article ; Pharmacology. Drug treatments ; Prostaglandins - analysis ; Prostaglandins E, Synthetic - pharmacology</subject><ispartof>British journal of cancer, 1985-08, Vol.52 (2), p.245-249</ispartof><rights>Cancer Research Campaign 1985</rights><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3614-3f6134011b4953fe34dfae144bd001459ea125aab855bf8a31016d52065ff5bf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977112/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977112/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27911,27912,53778,53780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8623688$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4027166$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bennett, A</creatorcontrib><creatorcontrib>Carroll, M A</creatorcontrib><creatorcontrib>Melhuish, P B</creatorcontrib><creatorcontrib>Stamford, I F</creatorcontrib><title>Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>WHT/Ht mice transplanted s.c. with NC carcinoma were treated with 16,16-dimethyl prostaglandin E2 methyl ester (di-me-PGE2) and/or indomethacin. Each primary tumour was excised under anaesthesia 3 weeks after transplantation, weighed and extracted for prostaglandins. Mouse survival time and tumour recurrence were measured. Di-me-PGE2 10 micrograms, injected at the tumour site on alternate days from day 1 to 19, indomethacin 2.5 mg kg-1 daily by mouth, or both drugs together resulted in lighter tumours (respectively 45, 45 and 52% less, n = 18 to 20 per group, P less than 0.02) compared with vehicle-treated controls. Indomethacin reduced the tumour prostaglandin yield, but the biological activity in extracts of tumours from mice given di-me-PGE2 was high. The median survival time was longer in mice receiving indomethacin alone (61 days from tumour transplantation compared with 50 days in controls P less than 0.02). Di-me-PGE2 alone had little or no effect on survival (median 48 days) but counteracted the increase with indomethacin (di-me-PGE2 + indomethacin, 49 days median survival). There were no obvious effects of the treatments on tumour recurrence at the excision site, but there was a higher incidence of involved lymph nodes in mice given di-me-PGE2.</description><subject>16,16-Dimethylprostaglandin E2 - pharmacology</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoma - analysis</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - pathology</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>General aspects</subject><subject>Indomethacin - antagonists & inhibitors</subject><subject>Indomethacin - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Molecular Medicine</subject><subject>Neoplasm Transplantation</subject><subject>Oncology</subject><subject>original-article</subject><subject>Pharmacology. Drug treatments</subject><subject>Prostaglandins - analysis</subject><subject>Prostaglandins E, Synthetic - pharmacology</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><recordid>eNptkc1v1DAQxS1EVZbCjStSDogTWTz-inNBQlWBSpV6KVytiWPvepXEi50s4r_HZVcrkHryx_t5xvMeIW-AroFy_bHb2TW0Wq5Bi2dkBZKzGjRrnpMVpbSpacvoC_Iy5105tlQ3l-RSUNaAUivy4yE5nEc3zVX01RiX7CqLyYYpjliFqTqEQ6x-hXlbYbVPMc-4GXDqi3LDKpxwiJvFlU1f4D6Obt5iefyKXHgcsnt9Wq_I9y83D9ff6rv7r7fXn-9qyxWImnsFXFCATrSSe8dF79GBEF1PKQjZOgQmETstZec1cqCgesmokt6XG35FPh3r7pdudL0tcyQczD6FEdNvEzGY_5UpbM0mHgy0TQPASoH3pwIp_lxcns0YsnVDmdEVM0yjmBTqL_jhCNpiQk7On5sANY85mJKDeczBlBwK_vbfj53hk_FFf3fSMVscfMLJhnzGtGJcaV2w-ojlokwbl8wuLqm4np9u-wcGSqAT</recordid><startdate>19850801</startdate><enddate>19850801</enddate><creator>Bennett, A</creator><creator>Carroll, M A</creator><creator>Melhuish, P B</creator><creator>Stamford, I F</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19850801</creationdate><title>Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin</title><author>Bennett, A ; Carroll, M A ; Melhuish, P B ; Stamford, I F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3614-3f6134011b4953fe34dfae144bd001459ea125aab855bf8a31016d52065ff5bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>16,16-Dimethylprostaglandin E2 - pharmacology</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoma - analysis</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - pathology</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>General aspects</topic><topic>Indomethacin - antagonists & inhibitors</topic><topic>Indomethacin - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Molecular Medicine</topic><topic>Neoplasm Transplantation</topic><topic>Oncology</topic><topic>original-article</topic><topic>Pharmacology. Drug treatments</topic><topic>Prostaglandins - analysis</topic><topic>Prostaglandins E, Synthetic - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bennett, A</creatorcontrib><creatorcontrib>Carroll, M A</creatorcontrib><creatorcontrib>Melhuish, P B</creatorcontrib><creatorcontrib>Stamford, I F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bennett, A</au><au>Carroll, M A</au><au>Melhuish, P B</au><au>Stamford, I F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1985-08-01</date><risdate>1985</risdate><volume>52</volume><issue>2</issue><spage>245</spage><epage>249</epage><pages>245-249</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>WHT/Ht mice transplanted s.c. with NC carcinoma were treated with 16,16-dimethyl prostaglandin E2 methyl ester (di-me-PGE2) and/or indomethacin. Each primary tumour was excised under anaesthesia 3 weeks after transplantation, weighed and extracted for prostaglandins. Mouse survival time and tumour recurrence were measured. Di-me-PGE2 10 micrograms, injected at the tumour site on alternate days from day 1 to 19, indomethacin 2.5 mg kg-1 daily by mouth, or both drugs together resulted in lighter tumours (respectively 45, 45 and 52% less, n = 18 to 20 per group, P less than 0.02) compared with vehicle-treated controls. Indomethacin reduced the tumour prostaglandin yield, but the biological activity in extracts of tumours from mice given di-me-PGE2 was high. The median survival time was longer in mice receiving indomethacin alone (61 days from tumour transplantation compared with 50 days in controls P less than 0.02). Di-me-PGE2 alone had little or no effect on survival (median 48 days) but counteracted the increase with indomethacin (di-me-PGE2 + indomethacin, 49 days median survival). There were no obvious effects of the treatments on tumour recurrence at the excision site, but there was a higher incidence of involved lymph nodes in mice given di-me-PGE2.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>4027166</pmid><doi>10.1038/bjc.1985.184</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0920 |
ispartof | British journal of cancer, 1985-08, Vol.52 (2), p.245-249 |
issn | 0007-0920 1532-1827 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1977112 |
source | PubMed Central |
subjects | 16,16-Dimethylprostaglandin E2 - pharmacology Animals Antineoplastic agents Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma - analysis Carcinoma - drug therapy Carcinoma - mortality Carcinoma - pathology Drug Resistance Epidemiology General aspects Indomethacin - antagonists & inhibitors Indomethacin - therapeutic use Male Medical sciences Mice Mice, Inbred Strains Molecular Medicine Neoplasm Transplantation Oncology original-article Pharmacology. Drug treatments Prostaglandins - analysis Prostaglandins E, Synthetic - pharmacology |
title | Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T18%3A50%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20mouse%20carcinoma%20in%20vivo%20with%20a%20prostaglandin%20E2%20analogue%20and%20indomethacin&rft.jtitle=British%20journal%20of%20cancer&rft.au=Bennett,%20A&rft.date=1985-08-01&rft.volume=52&rft.issue=2&rft.spage=245&rft.epage=249&rft.pages=245-249&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1985.184&rft_dat=%3Cproquest_pubme%3E76254612%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3614-3f6134011b4953fe34dfae144bd001459ea125aab855bf8a31016d52065ff5bf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=76254612&rft_id=info:pmid/4027166&rfr_iscdi=true |